JNJ-47910382 / J&J - LARVOL DELTA

Study in HCV-infected patients to determine the safety, tolerability, pharmacokinetics and antiviral activity of JNJ-47910382 (clinicaltrials.gov) - P1, N=40; Not yet recruiting; New P1 trial

New P1 trial • Hepatitis C Virus

A Study of the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-47910382 at Different Doses and Dose Regimens in Asian Genotype-1, Chronic, HCV-Infected Patients (clinicaltrials.gov) - P1; N=8; Terminated; Sponsor: Janssen R&D Ireland; N=18 ➔ 8; Recruiting ➔ Terminated; Because of many competing trials using the same mechanism of action, but being further advanced in development

Clinical • Enrollment change • Trial termination